免疫与靶向治疗联用：子宫内膜癌治疗新视角

doi:10.12280/gjfckx.20210290

摘要/Abstract

摘要：

子宫内膜癌（endometrial carcinoma）作为女性生殖系统三大恶性肿瘤之一,近年来发病率在世界范围内呈上升趋势。复发或转移性子宫内膜癌的预后较差,一线治疗包括铂类药物化疗或激素治疗,目前尚无标准的后续疗法。近年来,人们对子宫内膜癌分子生物学基础的认识有了很大进展,并找到了治疗子宫内膜癌的潜在靶点。靶向治疗如多腺苷二磷酸核糖聚合酶[poly(ADP-ribose) polymerase,PARP]抑制剂和免疫治疗如程序性死亡蛋白-1（programmed death-1,PD-1）及程序性死亡蛋白配体-1（programmed death ligand-1,PD-L1）抑制剂有可能有效对抗特定亚型的子宫内膜癌。临床研究表明,联合使用这些药物可能产生协同效应。现就PD-1/PD-L1抑制剂与PARP抑制剂单一或联合治疗子宫内膜癌的临床研究进展作一综述。

关键词: 子宫内膜肿瘤, 分子靶向治疗, 免疫疗法, 聚ADP核糖聚合酶类, 抗原,CD274, 程序性死亡蛋白配体-1, 程序性死亡蛋白-1

Abstract:

As one of the three major malignant tumors of female reproductive system, the incidence of endometrial carcinoma is increasing all over the world in recent years. The prognosis of recurrent or metastatic endometrial carcinoma is poor. First-line treatment includes platinum chemotherapy or hormone therapy. There is no standard follow-up therapy at present. In recent years, significant advances have been made in the understanding of the molecular basis of endometrial carcinoma, and potential targets for therapeutic endometrial carcinoma have been identified. Targeted therapy such as PARP inhibitors and immunotherapy such as PD-1/PD-L1 inhibitors may be effective against specific subtypes of endometrial cancer. Clinical studies have shown that the combined use of these drugs may have a synergistic effect. This article reviews the clinical research progress of PD-1/PD-L1 inhibitors and PARP inhibitors in the treatment of endometrial carcinoma.

Key words: Endometrial neoplasms, Molecular targeted therapy, Immunotherapy, Poly(ADP-ribose) polymerases, Antigens,CD274, PD-L1, PD-1

李莉, 芦小珊, 辛佳纯, 王晓慧. 免疫与靶向治疗联用：子宫内膜癌治疗新视角[J]. 国际妇产科学杂志, 2022, 49(1): 5-9.

LI Li, LU Xiao-shan, XIN Jia-chun, WANG Xiao-hui. Combination of Immunity and Targeted Therapy: A New Perspective on the Treatment of Endometrial Carcinoma[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 5-9.

参考文献 39

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. doi: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Van Arsdale A, Miller DT, Kuo DY, et al. Association of obesity with survival in patients with endometrial cancer[J]. Gynecol Oncol, 2019, 154(1):156-162. doi: 10.1016/j.ygyno.2019.03.258. doi: S0090-8258(19)30493-7 pmid: 31060820
[3]	Francis SR, Ager BJ, Do OA, et al. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy[J]. Gynecol Oncol, 2019, 154(1):38-44. doi: 10.1016/j.ygyno.2019.04.676. doi: S0090-8258(19)31174-6 pmid: 31029507
[4]	de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial[J]. Lancet Oncol, 2019, 20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. doi: 10.1016/S1470-2045(19)30395-X
[5]	Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review[J]. Int J Gynecol Cancer, 2007, 17(5):964-978. doi: 10.1111/j.1525-1438.2007.00897.x. doi: 10.1111/j.1525-1438.2007.00897.x pmid: 17442022
[6]	Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447):67-73. doi: 10.1038/nature12113. doi: 10.1038/nature12113
[7]	Eggink FA, Van Gool IC, Leary A, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition[J]. Oncoimmunology, 2017, 6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. doi: 10.1080/2162402X.2016.1264565
[8]	Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas[J]. Cell, 2018, 173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035. doi: S0092-8674(18)30359-3 pmid: 29625050
[9]	de Jonge MM, Auguste A, van Wijk LM, et al. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas[J]. Clin Cancer Res, 2019, 25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. doi: 10.1158/1078-0432.CCR-18-1443
[10]	Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody[J]. Cancer Immunol Res, 2015, 3(9):1052-1062. doi: 10.1158/2326-6066.CIR-14-0191. doi: 10.1158/2326-6066.CIR-14-0191 pmid: 25943534
[11]	Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. doi: 10.1146/annurev.immunol.26.021607.090331
[12]	Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma[J]. N Engl J Med, 2018, 379(4):341-351. doi: 10.1056/NEJMoa1805131. doi: 10.1056/NEJMoa1805131
[13]	Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study[J]. Breast Cancer Res Treat, 2018, 167(3):671-686. doi: 10.1007/s10549-017-4537-5. doi: 10.1007/s10549-017-4537-5
[14]	Li Z, Joehlin-Price AS, Rhoades J, et al. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency[J]. Int J Gynecol Cancer, 2018, 28(1):59-68. doi: 10.1097/IGC.0000000000001120. doi: 10.1097/IGC.0000000000001120
[15]	Sloan EA, Ring KL, Willis BC, et al. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors[J]. Am J Surg Pathol, 2017, 41(3):326-333. doi: 10.1097/PAS.0000000000000783. doi: 10.1097/PAS.0000000000000783
[16]	Sobecki-Rausch J, Barroilhet L. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors[J]. Curr Treat Options Oncol, 2019, 20(11):83. doi: 10.1007/s11864-019-0679-5. doi: 10.1007/s11864-019-0679-5
[17]	Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349):409-413. doi: 10.1126/science.aan6733. doi: 10.1126/science.aan6733
[18]	Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study[J]. J Clin Oncol, 2017, 35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. doi: 10.1200/JCO.2017.72.5952
[19]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019, 152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. doi: 10.1016/j.ygyno.2018.11.017
[20]	Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. doi: S1470-2045(17)30469-2 pmid: 28754483
[21]	Lim J, Tan D. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors[J]. Cancers(Basel), 2017, 9(8):109. doi: 10.3390/cancers9080109. doi: 10.3390/cancers9080109
[22]	Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer[J]. N Engl J Med, 2019, 381(25):2403-2415. doi: 10.1056/NEJMoa1909707. doi: 10.1056/NEJMoa1909707
[23]	Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505. doi: 10.1056/NEJMoa1810858. doi: 10.1056/NEJMoa1810858
[24]	Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation[J]. N Engl J Med, 2018, 379(8):753-763. doi: 10.1056/NEJMoa1802905. doi: 10.1056/NEJMoa1802905
[25]	Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017, 377(6):523-533. doi: 10.1056/NEJMoa1706450. doi: 10.1056/NEJMoa1706450
[26]	Stewart RA, Pilié PG, Yap TA. Development of PARP and Immune-Checkpoint Inhibitor Combinations[J]. Cancer Res, 2018, 78(24):6717-6725. doi: 10.1158/0008-5472.CAN-18-2652. doi: 10.1158/0008-5472.CAN-18-2652 pmid: 30498083
[27]	Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer[J]. J Clin Oncol, 2020, 38(26):2981-2992. doi: 10.1200/JCO.19.02627. doi: 10.1200/JCO.19.02627 pmid: 32167863
[28]	Taylor MH, Lee CH, Makker V, et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors[J]. J Clin Oncol, 2020, 38(11):1154-1163. doi: 10.1200/JCO.19.01598. doi: 10.1200/JCO.19.01598
[29]	Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer[J]. Cancer Discov, 2019, 9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218. doi: 10.1158/2159-8290.CD-18-1218
[30]	Ding L, Kim HJ, Wang Q, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer[J]. Cell Rep, 2018, 25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. doi: 10.1016/j.celrep.2018.11.054
[31]	Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression[J]. Clin Cancer Res, 2017, 23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. doi: 10.1158/1078-0432.CCR-16-3215
[32]	Bosse T, ter Haar NT, Seeber LM, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer[J]. Mod Pathol, 2013, 26(11):1525-1535. doi: 10.1038/modpathol.2013.96. doi: 10.1038/modpathol.2013.96
[33]	Shen J, Peng Y, Wei L, et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors[J]. Cancer Discov, 2015, 5(7):752-767. doi: 10.1158/2159-8290.CD-14-0849. doi: 10.1158/2159-8290.CD-14-0849
[34]	Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer[J]. JAMA Oncol, 2019, 5(8):1132-1140. doi: 10.1001/jamaoncol.2019.1029. doi: 10.1001/jamaoncol.2019.1029
[35]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma[J]. JAMA Oncol, 2019, 5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048. doi: 10.1001/jamaoncol.2019.1048
[36]	Lee JM, Cimino-Mathews A, Peer CJ, et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women′s Cancers: A Dose-Escalation, Phase I Study[J]. J Clin Oncol, 2017, 35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. doi: 10.1200/JCO.2016.72.1340
[37]	Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study[J]. Lancet Oncol, 2020, 21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. doi: S1470-2045(20)30324-7 pmid: 32771088
[38]	Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer[J]. J Clin Oncol, 2019, 37(30):2786-2794. doi: 10.1200/JCO.19.01021. doi: 10.1200/JCO.19.01021 pmid: 31461377
[39]	Musacchio L, Boccia SM, Caruso G, et al. Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?[J]. J Clin Med, 2020, 9(6):1721. doi: 10.3390/jcm9061721. doi: 10.3390/jcm9061721